BIVI Insider Trading

Insider Ownership Percentage: 4.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

BioVie Insider Trading History Chart

This chart shows the insider buying and selling history at BioVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

BioVie Share Price & Price History

Current Price: $0.98
Price Change: Price Increase of +0.144 (17.14%)
As of 04/2/2025 03:35 PM ET

This chart shows the closing price history over time for BIVI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.84Closing price on 04/01/25:

BioVie Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for BioVie (NASDAQ:BIVI)

4.59% of BioVie stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BIVI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$507kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$600k-$400k-$200k$0$200k$400k$600kTotal InflowsTotal Outflows
BioVie logo
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Read More on BioVie

Today's Range

Now: $0.98
Low: $0.80
High: $1.00

50 Day Range

MA: $1.44
Low: $0.84
High: $2.01

52 Week Range

Now: $0.98
Low: $0.82
High: $7.50

Volume

218,116 shs

Average Volume

1,742,643 shs

Market Capitalization

$18.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Who are the company insiders with the largest holdings of BioVie?

BioVie's top insider investors include:
  1. Steve Gorlin (Director)
  2. Cuong V Do (CEO)
  3. Richard J Berman (Director)
Learn More about top insider investors at BioVie.